Key facts
- It has raised $13.9M; the latest was Early Stage VC in Jan 2026.
- Notable investors include Legend Capital, Guangdong Technology Financial Group, Dunjun Capital, FengyunKunlun, Guangzhou Industrial Investment Holding Group — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for WePure Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for WePure Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About WePure Biotech
Manufacturer, provider and developer of microspheres intended for drug discovery, analysis, detection and testing. The company offers research and development of microspheres made of silica gel and resin, thereby enabling clients with stable and reproducible microspheres.
- Sector
- Materials and Resources
- HQ
- Guangzhou, China
- Founded
- 2022
- Website
- wepuretech.com/
- Ownership
- Privately Held (backing)
WePure Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in WePure Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on WePure Biotech in its N-PORT filings yet. We sweep new filings monthly.